H.C. Wainwright says Pyxis Oncology (PYXS) reported positive preliminary data from the ongoing Phase 1 study of PYX-201, an extra domain B splice variant of fibronectin targeted antibody-drug conjugate with a novel auristatin payload, in solid tumors. Despite early data from a limited number of patients, H.C. Wainwright is “impressed by the strong” overall response rate of 50% and the favorable safety and tolerability profile of the drug in heavily pre-treated patients with head and neck squamous cell carcinoma. The firm views the dataset as “compelling” and reiterates a Buy rating on the shares with a $7 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PYXS:
- Pyxis Oncology downgraded to Market Perform from Outperform at William Blair
- Closing Bell Movers: Nvidia down slightly after Q3 results
- Pyxis Oncology Reports Promising Phase 1 Trial Results
- Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck
- Pyxis Oncology reports Q3 EPS (35c), consensus (31c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
